Boston Scientific Corp
NYSE:BSX
Intrinsic Value
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. [ Read More ]
The intrinsic value of one BSX stock under the Base Case scenario is 52.78 USD. Compared to the current market price of 73.26 USD, Boston Scientific Corp is Overvalued by 28%.
Valuation Backtest
Boston Scientific Corp
Run backtest to discover the historical profit from buying and selling BSX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Boston Scientific Corp
Current Assets | 6.5B |
Cash & Short-Term Investments | 865m |
Receivables | 2.2B |
Other Current Assets | 3.4B |
Non-Current Assets | 28.6B |
Long-Term Investments | 413m |
PP&E | 3.3B |
Intangibles | 20.4B |
Other Non-Current Assets | 4.5B |
Current Liabilities | 4.9B |
Accounts Payable | 942m |
Accrued Liabilities | 2.5B |
Other Current Liabilities | 1.5B |
Non-Current Liabilities | 10.9B |
Long-Term Debt | 8.6B |
Other Non-Current Liabilities | 2.4B |
Earnings Waterfall
Boston Scientific Corp
Revenue
|
14.2B
USD
|
Cost of Revenue
|
-4.3B
USD
|
Gross Profit
|
9.9B
USD
|
Operating Expenses
|
-7.5B
USD
|
Operating Income
|
2.4B
USD
|
Other Expenses
|
-858m
USD
|
Net Income
|
1.6B
USD
|
Free Cash Flow Analysis
Boston Scientific Corp
BSX Profitability Score
Profitability Due Diligence
Boston Scientific Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Boston Scientific Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
BSX Solvency Score
Solvency Due Diligence
Boston Scientific Corp's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Boston Scientific Corp's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BSX Price Targets Summary
Boston Scientific Corp
According to Wall Street analysts, the average 1-year price target for BSX is 74.98 USD with a low forecast of 63.63 USD and a high forecast of 85.05 USD.
Ownership
BSX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BSX Price
Boston Scientific Corp
Average Annual Return | 7.01% |
Standard Deviation of Annual Returns | 20.73% |
Max Drawdown | -43% |
Market Capitalization | 107.4B USD |
Shares Outstanding | 1 476 900 000 |
Percentage of Shares Shorted | 0.85% |
BSX News
Last Important Events
Boston Scientific Corp
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Boston Scientific Corp
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. The company is headquartered in Marlborough, Massachusetts and currently employs 41,000 full-time employees. The Company’s business segments include MedSurg, Rhythm and Neuro, and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Pelvic Health. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal (GI) and pulmonary conditions. Its Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions. The Rhythm and Neuro segment include Cardiac Rhythm Management (CRM) and Electrophysiology. Its CRM develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions.
Contact
IPO
Employees
Officers
The intrinsic value of one BSX stock under the Base Case scenario is 52.78 USD.
Compared to the current market price of 73.26 USD, Boston Scientific Corp is Overvalued by 28%.